The results underscore the potential of our targeted delivery system to improve drug accumulation within SSTR2-positive tumor cells, thereby enhancing the therapeutic efficacy against cancer while reducing the likelihood of the adverse effects typically associated with nonspecific drug distribution, and not only inhibiting tumor progression but also inducing tumor regression in cases where receptor expression is maximally aligned with the targeting mechanism of the therapy. Here, SSTR2 is linked to cancer.